AstraZeneca account plan
Healthcare innovation through science
At a glance
AstraZeneca is a Cambridge, UK-based biopharmaceutical company with $58,739m of FY2025 Total Revenue and 96,100 employees.
AstraZeneca is a science-led biopharmaceutical company headquartered in Cambridge, UK, researching, developing, manufacturing and selling prescription medicines in Oncology, BioPharmaceuticals (CVRM, Respiratory & Immunology, Vaccines & Immune Therapies) and Rare Disease (Alexion). It has an active presence in more than 80 countries and sales in more than 125. FY2025 Total Revenue was $58,739m, up 9% (8% at CER), with Core Operating profit of $18,478m and Reported EPS of $6.60. It had 96,100 employees at end-2025. Its shares trade in London, Stockholm and, since 2 February 2026, directly on the NYSE; Pascal Soriot is CEO and Michel Demaré Chair.
Business units
Oncology
$25,619m FY2025 Total Revenue, 44% of Total RevenueCancer medicines including Tagrisso ($7,254m), Imfinzi ($6,063m), Calquence, Lynparza and Enhertu; revenue grew 15% in 2025 and 18% in H1 2026 to $14,124m. Led commercially by David Fredrickson and in R&D by Susan Galbraith.
BioPharmaceuticals - CVRM
$12,861m FY2025 Total RevenueCardiovascular, renal and metabolism medicines led by Farxiga ($8,492m), plus Crestor, Lokelma and Wainua; Baxfendy (baxdrostat) was approved in the US in May 2026. CVRM fell 8% in H1 2026 on Farxiga's US loss of exclusivity and China volume-based procurement.
BioPharmaceuticals - Respiratory & Immunology
$8,866m FY2025 Total RevenueRespiratory and immunology medicines such as Symbicort, Fasenra, Breztri, Tezspire and Saphnelo; revenue grew 13% in 2025 and 12% in H1 2026. BioPharmaceuticals is led by Ruud Dobber (business unit) and Sharon Barr (R&D).
BioPharmaceuticals - Vaccines & Immune Therapies
$1,268m FY2025 Total RevenueBeyfortus (with Sanofi), Synagis and FluMist; revenue fell 13% in 2025.
Rare Disease (Alexion)
$9,126m FY2025 Total Revenue, 16% of Total RevenueComplement medicines Ultomiris and Soliris plus Strensiq and Koselugo; revenue grew 4% in 2025 and 13% in H1 2026 to $4,911m. Led by Marc Dunoyer.
Other Medicines
2% of Total RevenueMature products outside the three therapy areas.
Strategic priorities
- Ambition 2030
- Launch at least 20 new medicines and reach $80 billion Total Revenue by 2030; 11 NMEs had been approved by July 2026.
- Transformative technologies
- ADCs, bispecifics, cell therapy, T-cell engagers, radioconjugates and genomic medicines; 16 Phase III trials of next-generation bispecifics run across 8 tumour types.
- Weight management and cardiovascular risk
- Five Phase III trials started for the oral GLP-1 elecoglipron, alongside baxdrostat and the oral PCSK9 laroprovstat.
- Enterprise AI
- An Enterprise AI unit was created in December 2025; over 90% of the small-molecule discovery pipeline is AI-enabled, and a Tempus partnership builds a model to predict trial success.
- US growth and localised supply
- The US is projected at about 50% of Total Revenue by 2030, and manufacturing is being built in the US and China so the regions can operate independently.
- Cost and systems efficiency
- A post-Alexion restructuring with $4.0 billion expected cost targets about $2.2 billion of run-rate benefits by end-2026, and the Axial ERP project runs to 2030.
Latest results
In H1 2026 Total Revenue was $30,672m, up 9% (6% at CER), and Q2 Total Revenue was $15,384m. Core Operating profit rose 12% to $10,510m (Core Operating Margin 34%) and Core EPS 12% to $5.21. Oncology grew 18% to $14,124m and Rare Disease 13% to $4,911m, while BioPharmaceuticals fell 1% to $11,151m as Farxiga and Brilinta lost exclusivity. Net debt rose $3,538m to $26,912m. FY2026 guidance was reconfirmed at CER: Total Revenue up a mid-to-high single-digit percentage and Core EPS up a low double-digit percentage.
Investments and deals
- $50 billion US programme
- Planned investment in US manufacturing and R&D, including a $4.5 billion plant in Charlottesville, Virginia and a $2 billion Maryland expansion.
- China and Singapore
- $2.5 billion for a Beijing R&D centre and manufacturing, and a $1.5 billion ADC plant in Singapore.
- Acquisitions and licences
- EsoBiotec (up to $1 billion), SixPeaks Bio and FibroGen China in 2025; in 2026 Zegfrovy from Dizal ($600m upfront) and TQC3721 from CTTQ ($200m upfront), plus a $1,104m upfront payment to CSPC.
- R&D and capex
- $14.2bn invested in R&D in 2025; FY2026 capex is expected to rise by about a third from $3,270m.
Challenges and risks
- Loss of exclusivity
- Farxiga's US loss of exclusivity coincides with its Medicare negotiated price from 2026, and Brilinta and roxadustat are also declining; BioPharmaceuticals is described as being in a transitional period.
- Pricing pressure
- IRA price negotiation for Farxiga and Calquence, US most-favoured-nation pricing, European generic erosion and China volume-based procurement.
- Pipeline setbacks
- CARDIO-TTRansform (Wainua in ATTR-CM) and EMERALD-2 failed their primary endpoints in 2026.
- Competition in China
- China revenue was flat at $3,510m in H1 2026, with intense competition in EGFR TKIs and ADCs.
- Geopolitics, tariffs and data
- Principal risks include tariff and trade-control volatility, cybersecurity and data and AI governance.
What leadership says
“While we are disappointed by the CARDIO-TTRansform outcome, we are on track to deliver our $80bn Total Revenue ambition, which assumes successes and setbacks.”
“we don't need additional BD if we continue delivering as we expect to across the pipeline.”
“Having AI tool is not sufficient. You have to have the data.”
“Our biopharmaceutical business is in a transitional period.”
Where a supplier can help
- Plant construction and equipment
- The $50 billion US programme, the Virginia and Maryland sites and the Singapore ADC plant, with capex up about a third in 2026, need engineering, equipment and automation suppliers.
- Data for AI in R&D
- The Enterprise AI unit and the CEO's point that AI needs data open room for data platforms, real-world data and AI infrastructure partners.
- Clinical trial execution
- 25 key Phase III readouts over 18 months and more than 100 Phase III studies point to CRO, trial-site and patient-recruitment services.
- ERP and efficiency programmes
- The Axial ERP project to 2030 and the restructuring programme fit systems integration and process automation services.
- Launch support
- Launches such as Baxfendy and pre-launch work for tozorakimab create demand for commercial, market access and medical engagement services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like AstraZeneca?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report and Form 20-F Information 2025
- AstraZeneca is a global, science-led biopharmaceutical company (HQ Cambridge, UK) organised around three therapy areas: Oncology, BioPharmaceuticals (CVRM, Respiratory & Immunology, Vaccines & Immune Therapies) and Rare Disease (Alexion); 96,100 employees at end-2025, active presence in more than 80 countries and sales in more than 125.
- FY2025 Total Revenue $58,739m, up 9% (8% at CER); Product Sales $55,573m, Alliance Revenue $3,067m (up 39%), Collaboration Revenue $99m (down 89%). Reported Operating profit $13,743m (up 37%), Core Operating profit $18,478m (up 9%); Reported EPS $6.60 (up 45%), Core EPS $9.16 (up 12%).
- Revenue mix: Oncology $25.6bn (44%), BioPharmaceuticals $23.0bn (39%), Rare Disease $9.1bn (16%); by region US $25.5bn (43%), Emerging Markets $15.3bn (26%), Europe $12.7bn (22%), Established Rest of World $5.2bn (9%). China Total Revenue $6,654m (up 4%).
- 16 blockbuster medicines; biggest products Farxiga ($8,492m), Tagrisso ($7,254m), Imfinzi ($6,063m, up 29%), Ultomiris ($4,718m), Calquence ($3,518m), Lynparza ($3,279m) and Enhertu ($2,775m, up 40%).
- Ambition 2030: at least 20 new medicines and $80 billion Total Revenue by 2030 (9 NMEs delivered so far); $14.2bn invested in R&D in 2025, 197 pipeline projects, 16 positive Phase III readouts, more than 100 Phase III studies ongoing.
- US is the largest market and is projected at about 50% of Total Revenue by 2030; October 2025 agreement with the US administration on prices plus a three-year Section 232 tariff exemption; plan to invest $50 billion in US manufacturing and R&D, including a $4.5 billion plant in Virginia and a $2 billion Maryland expansion.
- Other investments: $2.5 billion in a sixth strategic R&D centre and manufacturing in Beijing, a $1.5 billion ADC plant in Singapore; acquisitions of EsoBiotec (up to $1 billion), SixPeaks Bio and FibroGen China; new Enterprise AI unit created in December 2025 (over 90% of small-molecule discovery AI-enabled).
- Shares listed directly on the NYSE from 2 February 2026 (harmonised listing in London, Stockholm and New York, approved by 99.36% of votes); FY2025 dividend $3.20 (up 3%); Net debt $23,374m.
- 2026 guidance (CER): Total Revenue up a mid-to-high single-digit percentage, Core EPS up a low double-digit percentage, Core tax rate 18-22%.
- Key risks: pipeline failure or delay, pricing/affordability pressure (IRA: Farxiga's Medicare price from 2026 coinciding with US loss of exclusivity; Calquence from 2027), supply, cybersecurity and AI/data governance, litigation and IP, geopolitical and tariff volatility.
- AstraZeneca results: H1 and Q2 2026 (half-year financial report)
- H1 2026 Total Revenue $30,672m, up 9% (6% at CER); Q2 2026 $15,384m, up 6% (5% at CER). Alliance Revenue $1,699m, up 31%.
- Core EPS $5.21, up 12% (11% at CER); Reported EPS $3.60, up 4%. Core Operating profit $10,510m, up 12% (11% at CER), Core Operating Margin 34%.
- Oncology $14,124m (46% of revenue, up 18%, 15% at CER) and Rare Disease $4,911m (16%, up 13%) offset BioPharmaceuticals $11,151m (36%, down 1%, 5% at CER), where CVRM fell 8% (12% at CER) on Farxiga's US loss of exclusivity and China volume-based procurement.
- Regions: US $12,890m (42%, up 8%), Europe $6,822m (22%, up 17%), Emerging Markets $8,319m (27%, up 8%), of which China $3,510m flat (down 5% at CER), Established RoW $2,641m.
- Pipeline: Baxfendy (baxdrostat) approved in the US for hypertension in May 2026; Etcamah (camizestrant) approved in the EU and Japan; 30 approvals in major regions since Q4 2025 results; CARDIO-TTRansform (Wainua in ATTR-CM) failed its primary endpoint; sone-ve (CLARITY-Gastric01) and Imfinzi VOLGA positive.
- Business development: Zegfrovy licensed from Dizal ($600m upfront, up to $900m milestones); TQC3721 licence from CTTQ/Sino Biopharmaceutical ($200m upfront); $1,104m upfront paid to CSPC.
- Net debt rose $3,538m to $26,912m; capex $1,513m in H1, FY2026 capex expected up about a third; interim dividend $1.06, FY2026 dividend intended at $3.30.
- FY2026 guidance reconfirmed (CER): Total Revenue up a mid-to-high single-digit percentage, Core EPS up a low double-digit percentage. 9M/Q3 results due 30 October 2026.
- H1 and Q2 2026 results webinar for investors and analysts (transcript)
- Soriot: H1 2026 Total Revenue grew 6%, and 11% excluding Farxiga and Brilinta (hit by generics); Core EPS up 11%; 11 NMEs approved against the target of 20 by 2030.
- The $80 billion 2030 revenue ambition is "a risk-adjusted forecast" that already assumes setbacks such as the failed CARDIO-TTRansform trial for Wainua.
- Peak sales views raised: tozorakimab (COPD) to more than $5 billion; sone-ve (CLDN18.2 gastric ADC) $3-5 billion; Wainua, Etcamah and Baxfendy each more than $5 billion; efzimfotase alfa $3-5 billion.
- Oncology grew 15% to $14.1 billion (US 18%, Europe 16%); Calquence passed $1 billion in a quarter for the first time; Zegfrovy licensed to defend EGFR lung cancer leadership.
- BioPharmaceuticals is "in a transitional period": down 5% to $11.2 billion as Farxiga, Brilinta and roxadustat lose exclusivity, offset by Fasenra, Tezspire, Breztri and Saphnelo; elecoglipron (oral GLP-1) moved into Phase III.
- 25 key Phase III readouts planned over the next 18 months; 16 Phase III trials of next-generation bispecifics across 8 tumour types.
- CFO Aradhana Sarin: capex up around a third in 2026, about $2.5 billion of milestone payments expected for the year, BD upfronts of just over $2 billion year to date; R&D at the upper end of the low 20s percentage of revenue.
- Soriot: "we don't need additional BD" to grow after 2030; the plan assumes about 60% aggregate Phase III probability of success versus a 75%-plus record. Still "very bullish" on China, both as a market and as a source of innovation.
- How a Purpose-Led Culture Transformed AstraZeneca (with Pascal Soriot) — Positive Leadership podcast
- Long-form Positive Leadership podcast interview of CEO Pascal Soriot by Jean-Philippe, a former AstraZeneca board member (2008-2016), published on YouTube on 13 March 2026.
- Turnaround: when he joined in 2012 AstraZeneca sold $30 billion and was forecast to fall to $17-18 billion; it stabilised at $19-20 billion, sold older products to fund R&D and focused on oncology, cardiovascular and respiratory, later adding rare disease through Alexion.
- Culture: moved the company from a "marketing era" to science and patients, with values of following the science, putting patients first and taking risks; he refused a "we will not fail in phase three" mindset.
- Pfizer bid (2014): rejected because a merger would "totally distract us" from Tagrisso and Lynparza; the share price was 29-30 when he joined and around 140 today versus an offer that ended around 55 pounds.
- R&D economics: development takes "10 plus years"; his portfolio review committee meets twice a month and never approves less than 500 million of spend per meeting.
- Oncology: "we are starting to cure some cancers", by combining IO, ADCs, T-cell engagers and cell therapy.
- Geopolitics: supply chains are being localised in the US and China; Europe risks losing "its health sovereignty" within 15 years because governments treat pharma as a cost; China is "a massive contributor to innovation".
- AI: improves probability of success; partnership with Tempus to build a multimodal model predicting trial success, but "having AI tool is not sufficient. You have to have the data."
Questions about AstraZeneca
What does AstraZeneca do?
AstraZeneca researches, develops, manufactures and sells prescription medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and rare diseases.
What is AstraZeneca's revenue?
FY2025 Total Revenue was $58,739m, up 9%; H1 2026 Total Revenue was $30,672m.
How many employees does AstraZeneca have?
AstraZeneca had 96,100 employees at the end of 2025.
Who leads AstraZeneca?
Pascal Soriot is CEO, Michel Demaré is Chair and Aradhana Sarin is CFO.
What is AstraZeneca's strategy?
Ambition 2030 targets at least 20 new medicines and $80 billion Total Revenue by 2030, driven by transformative technologies such as ADCs and bispecifics.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)